Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement

Hirokazu Ogino(Tokushima University), Saburo Sone(Io Therapeutics (United States)), Yasuhiko Nishioka(Tokushima University), Hisatsugu Goto(Tokushima University), Seiji Yano(Kanazawa University Hospital), Masaki Hanibuchi(Tokushima University), Anderson J. Ryan(University of Oxford), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Kenji Ikuta(Nagoya City University), Tadaaki Yamada(Kyoto Prefectural University of Medicine), Emiko Nakataki(Tokushima University)
Cancer Letters
March 25, 2008
10.1016/j.canlet.2008.02.018
Cited by 1

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134